Literature DB >> 29160518

Evaluation of carbapenem-resistant Enterobacteriaceae in a tertiary-level reference hospital in Rio Grande do Sul, Brazil.

Vinícius Victor Lorenzoni1,2, Danielly da Costa Silva1,2, Roberta Filipini Rampelotto1,2, Patrícia Chaves Brites3, Bárbara Villa2,3, Rosmari Hörner1.   

Abstract

INTRODUCTION: The rapid global spread of carbapenem-resistant Enterobacteriaceae (CRE) is a threat to the health system.
METHODS: We evaluated the antimicrobial susceptibility profiles of 70 CRE isolated in a tertiary hospital in Brazil between August and December 2015, and determined their resistance mechanisms.
RESULTS: The most prevalent microorganism was Klebsiella pneumoniae (95.7%); it showed high-level resistance to carbapenems (>98%), with sensitivity to colistin (91.4%) and amikacin (98.6%). The bla KPC gene was detected in 80% of the CRE isolates.
CONCLUSIONS: Evaluation of bacterial resistance contributes to an appropriate treatment, and the reduction of morbimortality and dissemination of resistance.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29160518     DOI: 10.1590/0037-8682-0209-2017

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  3 in total

1.  Resistance Pattern of Carbapenem on Enterobacteriaceae.

Authors:  Khilasa Pokharel; Bishwa Raj Dawadi; Chandra Prakash Bhatt; Satish Gupte; Beena Jha
Journal:  JNMA J Nepal Med Assoc       Date:  2018 Nov-Dec       Impact factor: 0.406

2.  Rapid Identification of Carbapenemase-producing Klebsiella pneumoniae strains by Matrix-Assisted Laser Desorption/Ionization-Time of Flight using Vitek® Mass Spectrometry System.

Authors:  Vanessa Gaia Rocco; Jari Intra; Cecilia Sarto; Natalia Tiberti; Cinzia Savarino; Maura Brambilla; Paolo Brambilla
Journal:  Eurasian J Med       Date:  2019-10

Review 3.  Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects.

Authors:  Shio-Shin Jean; Nan-Yao Lee; Hung-Jen Tang; Min-Chi Lu; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2018-11-27       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.